anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Studies on the bench and at bedside have demonstrated that the process of epileptogenesis is involved in neuroinflammatory responses. As the receptor of proinflammatory cytokine IL-1β, IL-1β type 1 receptor (IL-1R1) is reported to express abundantly in the endothelial cells in epileptic brains, which is deemed to be implicated in the epileptogenic process. However, whether and how endothelial IL-1R1 modulates neuroinflammatory responses in the pathological process of epileptic seizures and/or status epilepticus (SE) remains obscure. Here, we indicated endothelial IL-1R1 is involved in neuroinflammation, facilitating epilepsy progress via Nrf2/HO-1/NLRP3. In vitro, we observed upregulation of inflammatory cytokines in co-culture model under IL-1β challenge, as well as in BV2 cells after stimulation with conditional medium (CM) from IL-1β-stimulated bEnd.3 cells. In vivo, mice with conditional knockout of endothelial IL-1R1 (IL-1R1-CKO) were generated by hybrid IL-1R1flox/flox mice with Tek-Cre mice. IL-1R1-CKO reduced seizure susceptibility in kainic acid (KA)-induced SE model. In addition, IL-1R1-CKO KA mice exhibited lessened hippocampal neuroinflammation, mitigated neuronal damage, and decreased abnormal neurogenesis. In cognitive behavioral tests, IL-1R1-CKO KA mice presented improvement in learning and memory. Furthermore, we also indicated blockage of endothelial IL-1R1 downregulated the expressions of Nrf2/HO-1/NLRP3 pathway-related proteins. Nrf2-siRNA reversed the downregulation of HO-1, NLRP3, caspase-1, and IL-1β. These results demonstrated CKO of endothelial IL-1R1 reduces seizure susceptibility and attenuates SE-related neurobehavioral damage by suppressing hippocampal neuroinflammation via Nrf2/HO-1/NLRP3.
FIELD: medicine. ^ SUBSTANCE: invention refers to chemical-pharmaceutical and medical industry. Common valerian roots and rhizomes are extracted in 70% ethyl alcohol with following filtration of the extract from herbal raw material. Extraction is aided with ultrasonic waves of frequency 30 kHz and intensity 365-370 Wt/cm2 during 18-20 minutes at temperature 25-27C at the relation of herbal raw material to 70% ethyl alcohol as 1:10. ^ EFFECT: invention allows improving yield and reducing preparation time of the product. ^ 2 cl, 1 dwg, 1 tbl, 1 ex
This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
The present invention discloses a kind of spray prepn. for preventing and curing exudative dermatitis, which is prepd. from fruit of melia toosemdan, flavescent sophora root, root of stemona, and camphor. It not only possesses of sterilizing, insecticidal, bactericidal, dampness-removing and itch-stopping etc. actions, but also possesses of a definite curative effect for fungi infection, recurrence of ecudative dermatitis and mosquito bites. Said invention features simple technological process, the product with fragrant smell of traditional Chinese medicine, non-toxic, harmless, no pollution to environment convenient for carrying and applying.
Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
In the prepn. of the medicinal mud (pack), peat is continuously comminuted in the presence of medicinal water. Drilling is carried out in a colloid mill for a predetermined time; e.g. in case of peat with 50% moisture content, at a ratio of peat:medicinal water 1:0.75-1, the milling period is 0.4-1.4 hrs. - Solid fraction over 63 micrometres is retained on a vibratory screen for removal after washing with medicinal water. The washing process increases the moisture content of the peat to 80-85%. The mud is concentrated for storage in the presence of a flocculating agent, and the clarified supernatant is removed by vacuum filtration. This lowers the moisture content to 35 vol.%. The mud is reconstituted by adding medicinal water before use.
In different areas of the heart, action potential waveforms differ due to differences in the expressions of sodium, calcium, and potassium channels. One of the characteristics of myocardial infarction (MI) is an imbalance in oxygen supply and demand, leading to ion imbalance. After MI, the regulation and expression levels of K+, Ca2+, and Na+ ion channels in cardiomyocytes are altered, which affects the regularity of cardiac rhythm and leads to myocardial injury. Myocardial fibroblasts are the main effector cells in the process of MI repair. The ion channels of myocardial fibroblasts play an important role in the process of MI. At the same time, a large number of ion channels are expressed in immune cells, which play an important role by regulating the in- and outflow of ions to complete intracellular signal transduction. Ion channels are widely distributed in a variety of cells and are attractive targets for drug development. This article reviews the changes in different ion channels after MI and the therapeutic drugs for these channels. We analyze the complex molecular mechanisms behind myocardial ion channel regulation and the challenges in ion channel drug therapy.
Cytogenomic analyses of acquired clonal chromosomal abnormalities in neoplastic blood, bone marrow, and/or lymph nodes are instrumental in the clinical management of patients with hematologic neoplasms. Cytogenetic analyses assist in the diagnosis of such disorders and can provide important prognostic information. Furthermore, cytogenetic studies can provide crucial information regarding specific genetically defined subtypes of these neoplasms that may have targeted therapies. At time of relapse, cytogenetic analysis can confirm recurrence of the original neoplasm, detect clonal disease evolution, or uncover a new unrelated neoplastic process. This section deals specifically with the technical standards applicable to cytogenomic studies of acquired clonal chromosomal abnormalities in neoplastic blood, bone marrow, and/or lymph nodes. This updated Section E6.1-6.6 supersedes the previous Section E6 in Section E: Clinical Cytogenetics of the American College of Medical Genetics and Genomics Technical Standards for Clinical Genetics Laboratories.
Small bowel capsule endoscopy is considered the diagnostic gold standard in the diagnosis of diseases of the small bowel. Most indications for capsule endoscopy are overt small bowel bleedings - defined as gastrointestinal bleeding after negative gastroscopy and colonoscopy - or occult iron deficiency anemia. Timing of small bowel capsule endoscopy seems to be decisive for the diagnosis of small bowel bleeding: corresponding to the actual guidelines the detection of small bowel bleeding can be up to \> 70% if the intervention is performed within 2 days. Treatment of small bowel bleedings can be performed with small bowel enteroscopy such as balloon or motorized spiral enteroscopy. Against this background this study investigates the rate of small bowel bleeding diagnosed in capsule endoscopy. The aim of the study is to report tumorous, vascular and inflammatory findings as well as complications and cecal accessibility. One focus of the study is the time between small bowel bleeding and small bowel capsule endoscopy and small bowel enteroscopy, respectively. Endoscopic therapies and further bleeding episodes are recorded. In order to determine the improved clinical outcome after the introduction of the shortened timing for recommendation published in 2022, a retrospective cohort should be included in addition to a prospective cohort.
Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) often leads to exertional intolerance and reduced exercise capacity, particularly in individuals previously admitted to an intensive care unit (ICU). However, the impact of invasive mechanical ventilation (IMV) on PASC-associated cardiorespiratory abnormalities during exercise remains poorly understood. This single-center, cross-sectional study aimed to gather knowledge on this topic. Fifty-two patients with PASC recruited ∼6 mo after ICU discharge were clustered based on their need for IMV (PASC + IMV, n = 27) or noninvasive support therapy (PASC + NIS, n = 25). Patients underwent pulmonary function and cardiopulmonary exercise testing (CPX) and were compared with a reference group (CONTROL, n = 19) comprising individuals of both sexes with similar age, comorbidities, and physical activity levels but without a history of COVID-19 illness. Individuals with PASC, irrespective of support therapy, presented with higher rates of cardiorespiratory abnormalities than CONTROL, especially dysfunctional breathing patterns, dynamic hyperinflation, reduced oxygen uptake and oxygen pulse, and blunted heart rate recovery (all P < 0.05). Only the rate of abnormal oxygen pulse was greater among PASC + IMV group than PASC + NIS group (P = 0.05). Mean estimates for all CPX variables were comparable between PASC + IMV and PASC + NIS groups (all P > 0.05). These findings indicate significant involvement of both central and peripheral factors, leading to exertional intolerance in individuals with PASC previously admitted to the ICU, regardless of their need for IMV.NEW & NOTEWORTHY We found cardiorespiratory abnormalities in ICU survivors of severe-to-critical COVID-19 with PASC to be independent of IMV need. Overall, both group of patients experienced dysfunctional breathing patterns, dynamic hyperinflation, lower oxygen uptake and oxygen pulse, and blunted heart rate responses to CPX. PASC seems to impact exertional tolerance and exercise capacity due to ventilatory inefficiency, impaired aerobic metabolism, and potential systolic and autonomic dysfunction, all of these irrespective of support therapy during ICU stay.
NEW MATERIAL:The compound of formula I [R<1> is 1-20C aliphatic acyl or (substituted) aromatic acyl; R<2> is H or OH-protecting group; R<3> is H or benzhydryl]. EXAMPLE:A carcinostatic agent having antitumor activity especially against cancer cells having Ara-C resistance. PROCESS:The compound of formula I a can be prepared, e.g. by reacting 3-deazauridine of formula II with diphenyl diazomethane in an inert solvent (e.g. hydrated acetone), reacting the obtained compound of formula III with an acid such as p-toluenesulfonic acid and ethyl orthoacetate in e.g. acetone, and acylating the resultant compound of formula IV. The obtained compound of formula I a can be converted to the compound of formula I b by removing the benzhydryl group and/or isopropylidene group therefrom.
<P>PROBLEM TO BE SOLVED: To provide a technique relating to a monoclonal antibody produced by a hybridoma of ATCC Accession No. HB10916.  <P>SOLUTION: The invention provides a monoclonal antibody bondable with a protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916. The invention further provides an isolated protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916, an isolated nucleic acid molecule encoding a protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916, and a human CD4-T cell leukemic cell of ATCC Accession No. CRL 10915 called as D1.1 and capable of essentially imparting a B cell with contact-dependent helper function.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention relates to a traditional Chinese medicine composition for treating gouty arthritis, which is prepared from the following raw material medicines in parts by weight: 14-16 parts of plantain herb, 8-10 parts of glabrous greenbrier rhizome and 3 parts of twotooth achyranthes root. The invention also provides the application of the traditional Chinese medicine composition. The monarch drug plantain herb in the invention is dry whole plantain herb of plantago, has sweet and cold nature and flavor, and enters liver, kidney, lung and small intestine channels. The medicine is mainly used for clearing heat and promoting urination, treating stranguria and eliminating phlegm, and cooling blood and removing toxicity. Rhizoma Smilacis Glabrae is a ministerial drug, is dried root of Liliaceae plant, and has sweet and mild taste and mild property. Has the effects of detoxifying, removing dampness and easing joint movement. Achyranthes root, radix Achyranthis bidentatae is a guiding drug, and has the effects of promoting blood circulation, removing blood stasis, and removing dampness and heat. The invention can treat the gouty arthritis without obvious adverse reaction, and has good patient compliance. The traditional Chinese medicine composition has obvious effect of reducing blood uric acid, has obvious effect of treating gouty arthritis, and is worthy of popularization.
Glucagon has been studied following intramuscular, subcutaneous, and intravenous administration in adult volunteers. Administration of the intravenous glucagon showed dose proportionality of the pharmacokinetics between 0.25 and 2.0 mg. Calculations from a 1 mg dose showed a small volume of distribution (mean, 0.25 L/kg) and a moderate clearance (mean, 13.5 mL/min/kg). The half-life was short, ranging from 8 to 18 minutes.

Maximum plasma concentrations of 7.9 ng/mL were achieved approximately 20 minutes after subcutaneous administration ( ). With intramuscular dosing, maximum plasma concentrations of 6.9 ng/mL were attained approximately 13 minutes after dosing. seeFigure 1A

Glucagon is extensively degraded in liver, kidney, and plasma. Urinary excretion of intact glucagon has not been measured.
This study will describe a initial experience in RALRP in Brazilian University Hospital. The follow-up of patients was performed as an examination at the medical consultation every three months. Complications were categorized according to the Clavien classification system. Biochemical failure was established by PSA level. Continence was defined as patients who remain dry and who do not require any kind of protection in their everyday activities. Sexual potency was defined as the ability to get and keep an erection for long enough to have satisfying sexual relations with or without the use of type-5 phosphodiesterase inhibitors (PDE-5) and a Sexual Health Inventory for Men (SHIM) score greater or equal to 21. Positive surgical margin is defined as the presence of neoplastic glands in direct contact with the ink on the surface of the piece, with no interposed connective tissue.
The ergot akaloids having a cyclol side chain are frequently used in medicine. It is the aim of the invention to obtain the alkaloid ergosine, which was not so easily accessible until now, by a convenient process and thus to supply it for pharmaceutical use. This is achieved with the aid of the strain IMET PA 134 of the species Claviceps purpurea (Fr) Tul. This was isolated from saprophytic alkaloid-free wild types by double mutation with the aid of a special selection route (e.g. on the basis of morphological changes). The said strain forms, in aerobic submerse or emerse culture in liquid nutrient media which contain a carbon source, a nitrogen source and mineral salts, at 20-30 DEG C, pH 4.0 - 6.2 in the course of 10-35 days, an alkaloid mixture of 90% ergosine/ergosinine and 10% clavine alkaloids with a total alkaloid content of 300-350  mu g of alkaloid per ml of nutrient solution.
Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
This is an open randomized controlled clinical pilot trial (Phase II). The study includes women with the International Federation of Obstetrics and Gynecology (FIGO) stage III-IV EOC selected for neoadjuvant chemotherapy (NACT) and without signs of thromboembolic disease or ongoing treatment of thromboembolic disease. The women will be allocated 1:1 to treatment with tinzaparin 4500 IU/8000 IU (dose depending on woman's weight) subcutaneously once daily or no tinzaparin. The treatment group starts tinzaparin when the primary treatment (chemotherapy) starts. The control group will not receive tinzaparin or other low molecular weight heparin preparations. The NACT consists of carboplatin and paclitaxel, given according to the standard regimen with cycle repeats every 21 days. Pre-treatment, before every cycle of chemotherapy, before delayed primary debulking surgery (DPDS) and three weeks after the last cycle of chemotherapy venous blood samples will be taken for measuring the biomarkers hemoglobin, platelets, leucocytes, C-reactive protein (CRP), albumin, cancer antigen-125 (CA-125), Tissue Factor, D-dimer, soluble P-selectin, thrombin-antithrombin complex and thrombin generation potential. Furthermore, a panel of 92 inflammation-associated proteins will be analyzed by a by a high-sensitivity Proximity Extension Assay at baseline, visit 5 and visit 8 or 9. After three cycles of NACT, the patient will be evaluated clinically and with imaging diagnostics in order to determine whether the patient should undergo DPDS. In the investigators´ setting, \> 80% of patients receiving NACT for EOC undergo DPDS. After DPDS, all patients will be treated with tinzaparin for 28 days according to clinical practice concerning postoperative thromboembolic prophylaxis and thereafter continue the chemotherapy for additional two-three courses. The participants who were allocated to tinzaparin during the NACT will continue the tinzaparin after ending the postoperative thromboembolic prophylactic tinzaparin treatment for additional 2-3 courses. The biomarkers will be measured preoperatively and four weeks postoperatively after DPDS and then before each course of chemotherapy given during the primary treatment. The women who do not undergo surgery will remain included in the study for the following three cycles of chemotherapy. Thus, the total study period constitutes 22-29 weeks.
<P>PROBLEM TO BE SOLVED: To provide a food digestion and excretion time confirming and discriminating body and a discrimination method that confirm the in vivo staying time of an ingested food, and when functions of digestive organs, particularly the function of large intestine is abnormal, a patient can undergo medical treatment and/or can receive improvement of dietary habits.  <P>SOLUTION: A natural food product difficult in digestion such as laver or cuttlefish ink or an artificial food product colored with an artificial dye capable of clearly coloring is used as a main material. A carrier as the discriminating body is prepared by forming the material into powder, gelatinous state, tablet or capsular form. The carrier is orally taken, and based on the presence of the color in feces, the retention time of the dye in vivo in terms of the intake of the dye to the primary excretion of the dye is obtained. Thereby, by comparing it with a retention time when body conditions are normal, the present conditions of a person including those of digesting organs can be presumed.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
INTRODUCTION: Atrial fibrillation (AF) is the most common sustained arrhythmia, and catheter ablation (CA) is a primary therapeutic option. However, the 30-day all-cause mortality risk associated with CA for AF may be underestimated due to selection bias. Our study aimed to assess 30-day mortality in an unselected cohort of patients.
METHODS: Data from the National Health Fund-Poland covered over 99% of nationwide radiofrequency ablation (RF) or cryoballoon ablation for AF, with 100% recorded deaths. The study included consecutive CA procedures in adult patients between 2012 and 2019. Thirty-day mortality rates were calculated for each age group.
RESULTS: A total of 31 214 CAs for AF were performed on 26 767 patients (34.8% female). Forty-four percent of patients had hypertension, 31.2% had coronary artery disease, 14.4% had heart failure, 11% had diabetes mellitus, 5.6% had malignant neoplasms, 2.7% had a previous myocardial infarction, 2.5% had a previous stroke, and 2.2% had kidney disease. Thirty-two deaths (0.1%) occurred within 30 days, with the highest mortality in the oldest age group (>80 years). Statistical analysis revealed higher incidences of kidney disease (p < 0.001) and heart failure (p = 0.001) in patients who died within 30 days. Mortality risk did not significantly differ between cryoballoon and RF ablation, as well as first and subsequent ablation for AF. The risk of death within 7 days postablation for AF was 1 in 2750 procedures, while the risk of death on the same day postablation was 1 in 6250 procedures.
CONCLUSIONS: The 30-day mortality rate in a large, unselected AF ablation cohort, covering 99% of procedures in the country, is low except for the oldest patients. This factor should be taken into consideration when offering CA for AF.
Subjects will recieve nutritional intervention by a registered dietitian and a supplement containing yellow colorant for 3 months. The dietary intervention consists of healthy dietary recommendations and hipocaloric diet if needed (overweight, obesity).
Post-treatment radiographic imaging change (PTRIC) is seen in approximately 50% of patients who are treated for brain neoplasms using chemotherapy and radiotherapy. PTRIC can be attributed to true disease progression or a form of benign radiographic enhancement, known in literature as pseudoprogression. Of these patients, 50% of them have benign radiographic enhancement that is usually spontaneously resolved and required no intervention. The other 50% require immediate medical intervention, or more aggressive treatment for true progression. Currently standard medical practise is to administer a prophylactic treatment of chemotherapy to all patients with PTRIC with a follow up scan 3-6 months after initial PTRIC diagnosis, leading to up to 50% of patients receiving an unneeded dose of chemotherapy. The investigators hope to take advantage of the differentiation in tissue types and vascularization between true progression tumour and pseudoprogression to be able to identify patients who would not need to be administered a prophylactic dose of chemotherapy.
PROBLEM TO BE SOLVED: To obtain a new DNA construct useful as e.g. a nucleic acid preparation consisting of a nucleic acid coding influenza virus gene, and capable of inducing influenza virus-specific immune reaction when transferred into biomedical tissue and taken into a cell. SOLUTION: This new DNA construct, which consists of a nucleic acid coding influenza virus gene, is capable of inducing expression of an antigenic influenza virus gene-forming substance capable of inducing influenza virus-specific immune reaction when transferred into biomedical tissue and thereby taken into a cell which is to express coded influenza virus gene, thus being useful as e.g. a polynucleotide vaccine for e.g. influenza virus phylaxis. This DNA construct is obtained by using influenza virus gene coding nucleoprotein, hemagglutinin, matrix, or nonstructural or polymerase gene-forming substance.
Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.